Screener
Neurocrine Biosciences NBIX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's EBITDA margin?
- Neurocrine Biosciences (NBIX) reported EBITDA margin of 26.4% in Q1 2026.
- How has Neurocrine Biosciences's EBITDA margin changed year-over-year?
- Neurocrine Biosciences's EBITDA margin increased by 21.7% year-over-year, from 21.7% to 26.4%.
- What is the long-term trend for Neurocrine Biosciences's EBITDA margin?
- Over 4 years (2020 to 2025), Neurocrine Biosciences's EBITDA margin has grown at a 8.4% compound annual growth rate (CAGR), from 16.4% to 22.7%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Neurocrine Biosciences's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude